Target Name: MLF1
NCBI ID: G4291
Review Report on MLF1 Target / Biomarker Content of Review Report on MLF1 Target / Biomarker
MLF1
Other Name(s): myelodysplasia-myeloid leukemia factor 1 | Myelodysplasia-myeloid leukemia factor 1 | MLF1 variant 1 | Myeloid leukemia factor 1 | MLF1_HUMAN | Myeloid leukemia factor 1 (isoform 1) | myeloid leukemia factor 1 | Myeloid leukemia factor 1, transcript variant 1 | testis tissue sperm-binding protein Li 49e

MLF1: A Potential Drug Target and Biomarker for Myelodysplasia-Myeloid Leukemia

Myelodysplasia-myeloid leukemia (MML) is a type of cancer that affects the bone marrow, where blood cells are produced. It is characterized by the uncontrolled proliferation of white blood cells called leukemia cells. MML is a rare and aggressive disease that has a high mortality rate, and there are currently no FDA-approved treatments available for it. However, research has identified a potential drug target and biomarker for MML, which could lead to new treatments for this disease.

The protein known as MLF1, which stands for myelodysplasia-myeloid leukemia factor 1, is a key regulator of the hematopoietic stem cell (HSC) proliferation and differentiation. It is a transmembrane protein that is expressed in the bone marrow and plays a critical role in the development and maintenance of normal blood cells.

Studies have shown that MLF1 is highly expressed in MML patient samples, and its levels are often elevated in the blood. Additionally, MLF1 has been shown to be involved in the regulation of HSC proliferation and the development of MML.

One of the key functions of MLF1 is its role in the regulation of the cell cycle. It is a transcription factor that can bind to specific DNA sequences and regulate the expression of genes. This function is critical for the development and maintenance of normal cell cycles, and is a potential drug target for MML.

Another function of MLF1 is its role in the regulation of cell survival. It has been shown to play a role in the regulation of apoptosis, which is the process by which cells die when they are no longer needed. This function is also a potential drug target for MML, as MML cells often have defective apoptosis regulation.

In addition to its functions in cell cycle and survival, MLF1 has also been shown to play a role in the regulation of inflammation. It has been shown to be involved in the regulation of immune cell function, and is therefore a potential biomarker for MML.

The identification of MLF1 as a potential drug target and biomarker for MML has important implications for the treatment of this disease. If MLF1 is effective as a drug target, it could lead to the development of new treatments for MML that target this protein and improve the treatment outcomes for patients. Additionally, if MLF1 is identified as a biomarker, it could be used to identify patients who are most likely to respond to a given treatment and improve the selection of patients for clinical trials.

In conclusion, MLF1 is a potential drug target and biomarker for MML. Its functions in cell cycle, survival, and inflammation make it an attractive target for new treatments for this disease. Further research is needed to fully understand the role of MLF1 in MML and to develop effective new treatments for this rare and aggressive cancer.

Protein Name: Myeloid Leukemia Factor 1

Functions: Involved in lineage commitment of primary hemopoietic progenitors by restricting erythroid formation and enhancing myeloid formation. Interferes with erythropoietin-induced erythroid terminal differentiation by preventing cells from exiting the cell cycle through suppression of CDKN1B/p27Kip1 levels. Suppresses COP1 activity via CSN3 which activates p53 and induces cell cycle arrest. Binds DNA and affects the expression of a number of genes so may function as a transcription factor in the nucleus

The "MLF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MLF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MLF1-DT | MLF2 | MLH1 | MLH3 | MLIP | MLIP-AS1 | MLKL | MLLT1 | MLLT10 | MLLT10P1 | MLLT11 | MLLT3 | MLLT6 | MLN | MLNR | MLPH | MLST8 | MLX | MLXIP | MLXIPL | MLYCD | MMAA | MMAB | MMACHC | MMADHC | MMADHC-DT | MMD | MMD2 | MME | MMEL1 | MMGT1 | MMP | MMP1 | MMP10 | MMP11 | MMP12 | MMP13 | MMP14 | MMP15 | MMP16 | MMP17 | MMP19 | MMP2 | MMP2-AS1 | MMP20 | MMP20-AS1 | MMP21 | MMP23A | MMP23B | MMP24 | MMP24-AS1-EDEM2 | MMP24OS | MMP25 | MMP25-AS1 | MMP26 | MMP27 | MMP28 | MMP3 | MMP7 | MMP8 | MMP9 | MMRN1 | MMRN2 | MMS19 | MMS22L | MMS22L-TONSL complex | MMUT | MMXD complex | MN1 | MNAT1 | MND1 | MNDA | MNS1 | MNT | MNX1 | MNX1-AS1 | MOAP1 | MOB1A | MOB1B | MOB2 | MOB3A | MOB3B | MOB3C | MOB4 | MOBP | MOCOS | MOCS1 | MOCS2 | MOCS2-DT | MOCS3 | MOG | MOGAT1 | MOGAT2 | MOGAT3 | MOGS | MOK | MON1A | MON1B | MON2 | Monoamine oxidase (MAO)